nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—CYP1B1—glaucoma	0.363	1	CbGaD
Erlotinib—SLCO2B1—Latanoprost—glaucoma	0.167	0.45	CbGbCtD
Erlotinib—CYP1A1—Clonidine—glaucoma	0.0235	0.0631	CbGbCtD
Erlotinib—CYP2D6—Carteolol—glaucoma	0.0233	0.0628	CbGbCtD
Erlotinib—CYP1A2—Betaxolol—glaucoma	0.0191	0.0514	CbGbCtD
Erlotinib—CYP2D6—Betaxolol—glaucoma	0.0158	0.0424	CbGbCtD
Erlotinib—CYP3A5—Clonidine—glaucoma	0.0141	0.0379	CbGbCtD
Erlotinib—CYP2D6—Methazolamide—glaucoma	0.0119	0.0321	CbGbCtD
Erlotinib—CYP3A4—Pilocarpine—glaucoma	0.0112	0.0302	CbGbCtD
Erlotinib—ABCB1—Timolol—glaucoma	0.0108	0.029	CbGbCtD
Erlotinib—CYP1A2—Clonidine—glaucoma	0.0105	0.0282	CbGbCtD
Erlotinib—CYP2D6—Timolol—glaucoma	0.0102	0.0273	CbGbCtD
Erlotinib—ABCB1—Clonidine—glaucoma	0.00916	0.0246	CbGbCtD
Erlotinib—CYP3A4—Brinzolamide—glaucoma	0.00882	0.0237	CbGbCtD
Erlotinib—CYP2D6—Clonidine—glaucoma	0.00863	0.0232	CbGbCtD
Erlotinib—CYP3A4—Dorzolamide—glaucoma	0.00852	0.0229	CbGbCtD
Erlotinib—CYP3A4—Methazolamide—glaucoma	0.00759	0.0204	CbGbCtD
Erlotinib—CYP3A4—Acetazolamide—glaucoma	0.00607	0.0163	CbGbCtD
Erlotinib—CYP3A4—Clonidine—glaucoma	0.00549	0.0148	CbGbCtD
Erlotinib—Vandetanib—VEGFA—glaucoma	0.00131	1	CrCbGaD
Erlotinib—MKNK1—Pindolol—Levobunolol—glaucoma	0.000965	0.276	CbGdCrCtD
Erlotinib—MKNK1—Pindolol—Carteolol—glaucoma	0.000965	0.276	CbGdCrCtD
Erlotinib—MKNK1—Pindolol—Metipranolol—glaucoma	0.00092	0.263	CbGdCrCtD
Erlotinib—MKNK1—Pindolol—Betaxolol—glaucoma	0.000644	0.184	CbGdCrCtD
Erlotinib—Dermatitis—Latanoprost—glaucoma	0.000178	0.00101	CcSEcCtD
Erlotinib—Dyspepsia—Acetazolamide—glaucoma	0.000178	0.00101	CcSEcCtD
Erlotinib—Mediastinal disorder—Clonidine—glaucoma	0.000177	0.00101	CcSEcCtD
Erlotinib—Headache—Latanoprost—glaucoma	0.000177	0.00101	CcSEcCtD
Erlotinib—Skin disorder—Brinzolamide—glaucoma	0.000177	0.00101	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Brimonidine—glaucoma	0.000177	0.00101	CcSEcCtD
Erlotinib—Anorexia—Dorzolamide—glaucoma	0.000177	0.00101	CcSEcCtD
Erlotinib—Arrhythmia—Clonidine—glaucoma	0.000176	0.001	CcSEcCtD
Erlotinib—Decreased appetite—Acetazolamide—glaucoma	0.000176	0.001	CcSEcCtD
Erlotinib—Insomnia—Brimonidine—glaucoma	0.000175	0.001	CcSEcCtD
Erlotinib—Oedema—Pilocarpine—glaucoma	0.000175	0.000998	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000175	0.000995	CcSEcCtD
Erlotinib—Fatigue—Acetazolamide—glaucoma	0.000174	0.000993	CcSEcCtD
Erlotinib—Infection—Pilocarpine—glaucoma	0.000174	0.000991	CcSEcCtD
Erlotinib—Alopecia—Clonidine—glaucoma	0.000174	0.000991	CcSEcCtD
Erlotinib—Nausea—Methazolamide—glaucoma	0.000173	0.000989	CcSEcCtD
Erlotinib—Dyspnoea—Brimonidine—glaucoma	0.000173	0.000986	CcSEcCtD
Erlotinib—Mental disorder—Clonidine—glaucoma	0.000172	0.000983	CcSEcCtD
Erlotinib—Shock—Pilocarpine—glaucoma	0.000172	0.000982	CcSEcCtD
Erlotinib—Thrombocytopenia—Pilocarpine—glaucoma	0.000171	0.000977	CcSEcCtD
Erlotinib—Erythema—Clonidine—glaucoma	0.000171	0.000976	CcSEcCtD
Erlotinib—Dyspepsia—Brimonidine—glaucoma	0.000171	0.000973	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Dorzolamide—glaucoma	0.000169	0.000962	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Travoprost—glaucoma	0.000168	0.000958	CcSEcCtD
Erlotinib—Insomnia—Dorzolamide—glaucoma	0.000168	0.000955	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Brimonidine—glaucoma	0.000168	0.000955	CcSEcCtD
Erlotinib—Fatigue—Brimonidine—glaucoma	0.000167	0.000953	CcSEcCtD
Erlotinib—Anorexia—Pilocarpine—glaucoma	0.000167	0.000951	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Brinzolamide—glaucoma	0.000166	0.000946	CcSEcCtD
Erlotinib—Pain—Brimonidine—glaucoma	0.000166	0.000946	CcSEcCtD
Erlotinib—Dyspnoea—Dorzolamide—glaucoma	0.000165	0.000942	CcSEcCtD
Erlotinib—Insomnia—Brinzolamide—glaucoma	0.000165	0.000939	CcSEcCtD
Erlotinib—Dyspnoea—Travoprost—glaucoma	0.000164	0.000937	CcSEcCtD
Erlotinib—Dyspepsia—Dorzolamide—glaucoma	0.000163	0.00093	CcSEcCtD
Erlotinib—Dyspnoea—Brinzolamide—glaucoma	0.000162	0.000926	CcSEcCtD
Erlotinib—Dyspepsia—Travoprost—glaucoma	0.000162	0.000926	CcSEcCtD
Erlotinib—Asthenia—Apraclonidine—glaucoma	0.000162	0.000924	CcSEcCtD
Erlotinib—Decreased appetite—Dorzolamide—glaucoma	0.000161	0.000918	CcSEcCtD
Erlotinib—Dyspepsia—Brinzolamide—glaucoma	0.00016	0.000914	CcSEcCtD
Erlotinib—Eye disorder—Betaxolol—glaucoma	0.00016	0.000913	CcSEcCtD
Erlotinib—Pruritus—Apraclonidine—glaucoma	0.00016	0.000911	CcSEcCtD
Erlotinib—Body temperature increased—Acetazolamide—glaucoma	0.00016	0.000911	CcSEcCtD
Erlotinib—Fatigue—Dorzolamide—glaucoma	0.00016	0.000911	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Pilocarpine—glaucoma	0.00016	0.000909	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Travoprost—glaucoma	0.000159	0.000908	CcSEcCtD
Erlotinib—Fatigue—Travoprost—glaucoma	0.000159	0.000907	CcSEcCtD
Erlotinib—Pain—Dorzolamide—glaucoma	0.000158	0.000903	CcSEcCtD
Erlotinib—Insomnia—Pilocarpine—glaucoma	0.000158	0.000903	CcSEcCtD
Erlotinib—Decreased appetite—Brinzolamide—glaucoma	0.000158	0.000903	CcSEcCtD
Erlotinib—Weight decreased—Timolol—glaucoma	0.000158	0.000902	CcSEcCtD
Erlotinib—Pain—Travoprost—glaucoma	0.000158	0.000899	CcSEcCtD
Erlotinib—Constipation—Travoprost—glaucoma	0.000158	0.000899	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000157	0.000896	CcSEcCtD
Erlotinib—Asthenia—Bimatoprost—glaucoma	0.000157	0.000896	CcSEcCtD
Erlotinib—Fatigue—Brinzolamide—glaucoma	0.000157	0.000895	CcSEcCtD
Erlotinib—Dyspnoea—Pilocarpine—glaucoma	0.000156	0.00089	CcSEcCtD
Erlotinib—Pain—Brinzolamide—glaucoma	0.000156	0.000888	CcSEcCtD
Erlotinib—Depression—Timolol—glaucoma	0.000155	0.000886	CcSEcCtD
Erlotinib—Pruritus—Bimatoprost—glaucoma	0.000155	0.000884	CcSEcCtD
Erlotinib—Diarrhoea—Apraclonidine—glaucoma	0.000155	0.000881	CcSEcCtD
Erlotinib—Mediastinal disorder—Betaxolol—glaucoma	0.000154	0.00088	CcSEcCtD
Erlotinib—Dyspepsia—Pilocarpine—glaucoma	0.000154	0.000878	CcSEcCtD
Erlotinib—Chills—Betaxolol—glaucoma	0.000154	0.000876	CcSEcCtD
Erlotinib—Syncope—Clonidine—glaucoma	0.000154	0.000876	CcSEcCtD
Erlotinib—Arrhythmia—Betaxolol—glaucoma	0.000153	0.000872	CcSEcCtD
Erlotinib—Decreased appetite—Pilocarpine—glaucoma	0.000152	0.000867	CcSEcCtD
Erlotinib—Conjunctivitis—Timolol—glaucoma	0.000152	0.000864	CcSEcCtD
Erlotinib—Gastrointestinal pain—Dorzolamide—glaucoma	0.000152	0.000864	CcSEcCtD
Erlotinib—Alopecia—Betaxolol—glaucoma	0.000151	0.000863	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000151	0.000862	CcSEcCtD
Erlotinib—Gastrointestinal pain—Travoprost—glaucoma	0.000151	0.00086	CcSEcCtD
Erlotinib—Loss of consciousness—Clonidine—glaucoma	0.000151	0.000858	CcSEcCtD
Erlotinib—Mental disorder—Betaxolol—glaucoma	0.00015	0.000856	CcSEcCtD
Erlotinib—Pain—Pilocarpine—glaucoma	0.00015	0.000853	CcSEcCtD
Erlotinib—Constipation—Pilocarpine—glaucoma	0.00015	0.000853	CcSEcCtD
Erlotinib—Cough—Clonidine—glaucoma	0.00015	0.000852	CcSEcCtD
Erlotinib—Dizziness—Apraclonidine—glaucoma	0.000149	0.000852	CcSEcCtD
Erlotinib—Malnutrition—Betaxolol—glaucoma	0.000149	0.00085	CcSEcCtD
Erlotinib—Erythema—Betaxolol—glaucoma	0.000149	0.00085	CcSEcCtD
Erlotinib—Epistaxis—Timolol—glaucoma	0.000147	0.000838	CcSEcCtD
Erlotinib—Abdominal pain—Dorzolamide—glaucoma	0.000146	0.000835	CcSEcCtD
Erlotinib—Body temperature increased—Dorzolamide—glaucoma	0.000146	0.000835	CcSEcCtD
Erlotinib—Chest pain—Clonidine—glaucoma	0.000146	0.000831	CcSEcCtD
Erlotinib—Arthralgia—Clonidine—glaucoma	0.000146	0.000831	CcSEcCtD
Erlotinib—Abdominal pain—Travoprost—glaucoma	0.000146	0.000831	CcSEcCtD
Erlotinib—Anxiety—Clonidine—glaucoma	0.000145	0.000828	CcSEcCtD
Erlotinib—Asthenia—Acetazolamide—glaucoma	0.000145	0.000827	CcSEcCtD
Erlotinib—Dizziness—Bimatoprost—glaucoma	0.000145	0.000826	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000145	0.000826	CcSEcCtD
Erlotinib—Vomiting—Apraclonidine—glaucoma	0.000144	0.000819	CcSEcCtD
Erlotinib—Gastrointestinal pain—Pilocarpine—glaucoma	0.000143	0.000816	CcSEcCtD
Erlotinib—Dermatitis—Apraclonidine—glaucoma	0.000142	0.000811	CcSEcCtD
Erlotinib—Headache—Apraclonidine—glaucoma	0.000142	0.000807	CcSEcCtD
Erlotinib—Oedema—Clonidine—glaucoma	0.00014	0.000797	CcSEcCtD
Erlotinib—Asthenia—Brimonidine—glaucoma	0.000139	0.000793	CcSEcCtD
Erlotinib—Infection—Clonidine—glaucoma	0.000139	0.000792	CcSEcCtD
Erlotinib—Abdominal pain—Pilocarpine—glaucoma	0.000138	0.000789	CcSEcCtD
Erlotinib—Body temperature increased—Pilocarpine—glaucoma	0.000138	0.000789	CcSEcCtD
Erlotinib—Diarrhoea—Acetazolamide—glaucoma	0.000138	0.000788	CcSEcCtD
Erlotinib—Rash—Bimatoprost—glaucoma	0.000138	0.000787	CcSEcCtD
Erlotinib—Dermatitis—Bimatoprost—glaucoma	0.000138	0.000787	CcSEcCtD
Erlotinib—Shock—Clonidine—glaucoma	0.000138	0.000784	CcSEcCtD
Erlotinib—Connective tissue disorder—Timolol—glaucoma	0.000138	0.000784	CcSEcCtD
Erlotinib—Pruritus—Brimonidine—glaucoma	0.000137	0.000782	CcSEcCtD
Erlotinib—Headache—Bimatoprost—glaucoma	0.000137	0.000782	CcSEcCtD
Erlotinib—Nervous system disorder—Clonidine—glaucoma	0.000137	0.000782	CcSEcCtD
Erlotinib—Thrombocytopenia—Clonidine—glaucoma	0.000137	0.00078	CcSEcCtD
Erlotinib—Skin disorder—Clonidine—glaucoma	0.000136	0.000774	CcSEcCtD
Erlotinib—Nausea—Apraclonidine—glaucoma	0.000134	0.000765	CcSEcCtD
Erlotinib—Syncope—Betaxolol—glaucoma	0.000134	0.000762	CcSEcCtD
Erlotinib—Dizziness—Acetazolamide—glaucoma	0.000134	0.000762	CcSEcCtD
Erlotinib—Anorexia—Clonidine—glaucoma	0.000133	0.00076	CcSEcCtD
Erlotinib—Asthenia—Dorzolamide—glaucoma	0.000133	0.000758	CcSEcCtD
Erlotinib—Asthenia—Travoprost—glaucoma	0.000132	0.000754	CcSEcCtD
Erlotinib—Pruritus—Dorzolamide—glaucoma	0.000131	0.000747	CcSEcCtD
Erlotinib—Loss of consciousness—Betaxolol—glaucoma	0.000131	0.000747	CcSEcCtD
Erlotinib—Eye disorder—Timolol—glaucoma	0.000131	0.000746	CcSEcCtD
Erlotinib—Asthenia—Brinzolamide—glaucoma	0.000131	0.000745	CcSEcCtD
Erlotinib—Pruritus—Travoprost—glaucoma	0.000131	0.000744	CcSEcCtD
Erlotinib—Cough—Betaxolol—glaucoma	0.00013	0.000742	CcSEcCtD
Erlotinib—Nausea—Bimatoprost—glaucoma	0.00013	0.000742	CcSEcCtD
Erlotinib—Pruritus—Brinzolamide—glaucoma	0.000129	0.000735	CcSEcCtD
Erlotinib—Vomiting—Acetazolamide—glaucoma	0.000129	0.000733	CcSEcCtD
Erlotinib—Dizziness—Brimonidine—glaucoma	0.000128	0.000731	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Clonidine—glaucoma	0.000127	0.000726	CcSEcCtD
Erlotinib—Arthralgia—Betaxolol—glaucoma	0.000127	0.000724	CcSEcCtD
Erlotinib—Chest pain—Betaxolol—glaucoma	0.000127	0.000724	CcSEcCtD
Erlotinib—Myalgia—Betaxolol—glaucoma	0.000127	0.000724	CcSEcCtD
Erlotinib—Diarrhoea—Dorzolamide—glaucoma	0.000127	0.000723	CcSEcCtD
Erlotinib—Headache—Acetazolamide—glaucoma	0.000127	0.000722	CcSEcCtD
Erlotinib—Anxiety—Betaxolol—glaucoma	0.000127	0.000721	CcSEcCtD
Erlotinib—Insomnia—Clonidine—glaucoma	0.000126	0.000721	CcSEcCtD
Erlotinib—Diarrhoea—Travoprost—glaucoma	0.000126	0.000719	CcSEcCtD
Erlotinib—Mediastinal disorder—Timolol—glaucoma	0.000126	0.000719	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000126	0.000719	CcSEcCtD
Erlotinib—Asthenia—Pilocarpine—glaucoma	0.000126	0.000716	CcSEcCtD
Erlotinib—Arrhythmia—Timolol—glaucoma	0.000125	0.000713	CcSEcCtD
Erlotinib—Dyspnoea—Clonidine—glaucoma	0.000125	0.00071	CcSEcCtD
Erlotinib—Diarrhoea—Brinzolamide—glaucoma	0.000125	0.00071	CcSEcCtD
Erlotinib—Pruritus—Pilocarpine—glaucoma	0.000124	0.000706	CcSEcCtD
Erlotinib—Alopecia—Timolol—glaucoma	0.000124	0.000705	CcSEcCtD
Erlotinib—Mental disorder—Timolol—glaucoma	0.000123	0.000699	CcSEcCtD
Erlotinib—Dizziness—Dorzolamide—glaucoma	0.000123	0.000698	CcSEcCtD
Erlotinib—Rash—Brimonidine—glaucoma	0.000122	0.000697	CcSEcCtD
Erlotinib—Dermatitis—Brimonidine—glaucoma	0.000122	0.000697	CcSEcCtD
Erlotinib—Dizziness—Travoprost—glaucoma	0.000122	0.000695	CcSEcCtD
Erlotinib—Erythema—Timolol—glaucoma	0.000122	0.000694	CcSEcCtD
Erlotinib—Malnutrition—Timolol—glaucoma	0.000122	0.000694	CcSEcCtD
Erlotinib—Oedema—Betaxolol—glaucoma	0.000122	0.000694	CcSEcCtD
Erlotinib—Headache—Brimonidine—glaucoma	0.000122	0.000693	CcSEcCtD
Erlotinib—Decreased appetite—Clonidine—glaucoma	0.000122	0.000693	CcSEcCtD
Erlotinib—Infection—Betaxolol—glaucoma	0.000121	0.000689	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Clonidine—glaucoma	0.000121	0.000688	CcSEcCtD
Erlotinib—Fatigue—Clonidine—glaucoma	0.000121	0.000687	CcSEcCtD
Erlotinib—Dizziness—Brinzolamide—glaucoma	0.00012	0.000687	CcSEcCtD
Erlotinib—Nausea—Acetazolamide—glaucoma	0.00012	0.000684	CcSEcCtD
Erlotinib—Diarrhoea—Pilocarpine—glaucoma	0.00012	0.000683	CcSEcCtD
Erlotinib—Shock—Betaxolol—glaucoma	0.00012	0.000683	CcSEcCtD
Erlotinib—Constipation—Clonidine—glaucoma	0.00012	0.000681	CcSEcCtD
Erlotinib—Pain—Clonidine—glaucoma	0.00012	0.000681	CcSEcCtD
Erlotinib—Nervous system disorder—Betaxolol—glaucoma	0.000119	0.00068	CcSEcCtD
Erlotinib—Thrombocytopenia—Betaxolol—glaucoma	0.000119	0.000679	CcSEcCtD
Erlotinib—Skin disorder—Betaxolol—glaucoma	0.000118	0.000674	CcSEcCtD
Erlotinib—Vomiting—Dorzolamide—glaucoma	0.000118	0.000671	CcSEcCtD
Erlotinib—Rash—Dorzolamide—glaucoma	0.000117	0.000666	CcSEcCtD
Erlotinib—Dermatitis—Dorzolamide—glaucoma	0.000117	0.000665	CcSEcCtD
Erlotinib—Rash—Travoprost—glaucoma	0.000116	0.000663	CcSEcCtD
Erlotinib—Dermatitis—Travoprost—glaucoma	0.000116	0.000662	CcSEcCtD
Erlotinib—Headache—Dorzolamide—glaucoma	0.000116	0.000662	CcSEcCtD
Erlotinib—Anorexia—Betaxolol—glaucoma	0.000116	0.000661	CcSEcCtD
Erlotinib—Vomiting—Brinzolamide—glaucoma	0.000116	0.00066	CcSEcCtD
Erlotinib—Dizziness—Pilocarpine—glaucoma	0.000116	0.00066	CcSEcCtD
Erlotinib—Headache—Travoprost—glaucoma	0.000116	0.000659	CcSEcCtD
Erlotinib—Nausea—Brimonidine—glaucoma	0.000115	0.000657	CcSEcCtD
Erlotinib—Rash—Brinzolamide—glaucoma	0.000115	0.000655	CcSEcCtD
Erlotinib—Dermatitis—Brinzolamide—glaucoma	0.000115	0.000654	CcSEcCtD
Erlotinib—Gastrointestinal pain—Clonidine—glaucoma	0.000114	0.000652	CcSEcCtD
Erlotinib—Headache—Brinzolamide—glaucoma	0.000114	0.00065	CcSEcCtD
Erlotinib—Vomiting—Pilocarpine—glaucoma	0.000111	0.000634	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000111	0.000632	CcSEcCtD
Erlotinib—Abdominal pain—Clonidine—glaucoma	0.000111	0.00063	CcSEcCtD
Erlotinib—Body temperature increased—Clonidine—glaucoma	0.000111	0.00063	CcSEcCtD
Erlotinib—Rash—Pilocarpine—glaucoma	0.00011	0.000629	CcSEcCtD
Erlotinib—Dermatitis—Pilocarpine—glaucoma	0.00011	0.000629	CcSEcCtD
Erlotinib—Insomnia—Betaxolol—glaucoma	0.00011	0.000628	CcSEcCtD
Erlotinib—Nausea—Dorzolamide—glaucoma	0.00011	0.000627	CcSEcCtD
Erlotinib—Headache—Pilocarpine—glaucoma	0.00011	0.000625	CcSEcCtD
Erlotinib—Nausea—Travoprost—glaucoma	0.00011	0.000625	CcSEcCtD
Erlotinib—Syncope—Timolol—glaucoma	0.000109	0.000623	CcSEcCtD
Erlotinib—Dyspnoea—Betaxolol—glaucoma	0.000109	0.000619	CcSEcCtD
Erlotinib—Nausea—Brinzolamide—glaucoma	0.000108	0.000617	CcSEcCtD
Erlotinib—Dyspepsia—Betaxolol—glaucoma	0.000107	0.000611	CcSEcCtD
Erlotinib—Loss of consciousness—Timolol—glaucoma	0.000107	0.00061	CcSEcCtD
Erlotinib—Cough—Timolol—glaucoma	0.000106	0.000606	CcSEcCtD
Erlotinib—Decreased appetite—Betaxolol—glaucoma	0.000106	0.000603	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Betaxolol—glaucoma	0.000105	0.000599	CcSEcCtD
Erlotinib—Fatigue—Betaxolol—glaucoma	0.000105	0.000598	CcSEcCtD
Erlotinib—Pain—Betaxolol—glaucoma	0.000104	0.000593	CcSEcCtD
Erlotinib—Constipation—Betaxolol—glaucoma	0.000104	0.000593	CcSEcCtD
Erlotinib—Nausea—Pilocarpine—glaucoma	0.000104	0.000593	CcSEcCtD
Erlotinib—Myalgia—Timolol—glaucoma	0.000104	0.000591	CcSEcCtD
Erlotinib—Arthralgia—Timolol—glaucoma	0.000104	0.000591	CcSEcCtD
Erlotinib—Chest pain—Timolol—glaucoma	0.000104	0.000591	CcSEcCtD
Erlotinib—Anxiety—Timolol—glaucoma	0.000103	0.000589	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000103	0.000587	CcSEcCtD
Erlotinib—Asthenia—Clonidine—glaucoma	0.0001	0.000572	CcSEcCtD
Erlotinib—Oedema—Timolol—glaucoma	9.94e-05	0.000567	CcSEcCtD
Erlotinib—Pruritus—Clonidine—glaucoma	9.89e-05	0.000564	CcSEcCtD
Erlotinib—Infection—Timolol—glaucoma	9.88e-05	0.000563	CcSEcCtD
Erlotinib—Shock—Timolol—glaucoma	9.78e-05	0.000558	CcSEcCtD
Erlotinib—Nervous system disorder—Timolol—glaucoma	9.75e-05	0.000556	CcSEcCtD
Erlotinib—Skin disorder—Timolol—glaucoma	9.66e-05	0.000551	CcSEcCtD
Erlotinib—Body temperature increased—Betaxolol—glaucoma	9.62e-05	0.000548	CcSEcCtD
Erlotinib—Diarrhoea—Clonidine—glaucoma	9.57e-05	0.000545	CcSEcCtD
Erlotinib—Anorexia—Timolol—glaucoma	9.48e-05	0.00054	CcSEcCtD
Erlotinib—Dizziness—Clonidine—glaucoma	9.25e-05	0.000527	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Timolol—glaucoma	9.06e-05	0.000516	CcSEcCtD
Erlotinib—Insomnia—Timolol—glaucoma	8.99e-05	0.000513	CcSEcCtD
Erlotinib—Vomiting—Clonidine—glaucoma	8.89e-05	0.000507	CcSEcCtD
Erlotinib—Dyspnoea—Timolol—glaucoma	8.87e-05	0.000505	CcSEcCtD
Erlotinib—Rash—Clonidine—glaucoma	8.82e-05	0.000502	CcSEcCtD
Erlotinib—Dermatitis—Clonidine—glaucoma	8.81e-05	0.000502	CcSEcCtD
Erlotinib—Headache—Clonidine—glaucoma	8.76e-05	0.000499	CcSEcCtD
Erlotinib—Dyspepsia—Timolol—glaucoma	8.75e-05	0.000499	CcSEcCtD
Erlotinib—Asthenia—Betaxolol—glaucoma	8.73e-05	0.000498	CcSEcCtD
Erlotinib—Decreased appetite—Timolol—glaucoma	8.65e-05	0.000493	CcSEcCtD
Erlotinib—Pruritus—Betaxolol—glaucoma	8.61e-05	0.000491	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Timolol—glaucoma	8.59e-05	0.000489	CcSEcCtD
Erlotinib—Fatigue—Timolol—glaucoma	8.57e-05	0.000489	CcSEcCtD
Erlotinib—Pain—Timolol—glaucoma	8.5e-05	0.000485	CcSEcCtD
Erlotinib—Diarrhoea—Betaxolol—glaucoma	8.33e-05	0.000475	CcSEcCtD
Erlotinib—Nausea—Clonidine—glaucoma	8.31e-05	0.000473	CcSEcCtD
Erlotinib—Gastrointestinal pain—Timolol—glaucoma	8.13e-05	0.000463	CcSEcCtD
Erlotinib—Dizziness—Betaxolol—glaucoma	8.05e-05	0.000459	CcSEcCtD
Erlotinib—Abdominal pain—Timolol—glaucoma	7.86e-05	0.000448	CcSEcCtD
Erlotinib—Body temperature increased—Timolol—glaucoma	7.86e-05	0.000448	CcSEcCtD
Erlotinib—Vomiting—Betaxolol—glaucoma	7.74e-05	0.000441	CcSEcCtD
Erlotinib—Rash—Betaxolol—glaucoma	7.68e-05	0.000437	CcSEcCtD
Erlotinib—Dermatitis—Betaxolol—glaucoma	7.67e-05	0.000437	CcSEcCtD
Erlotinib—Headache—Betaxolol—glaucoma	7.63e-05	0.000435	CcSEcCtD
Erlotinib—Nausea—Betaxolol—glaucoma	7.23e-05	0.000412	CcSEcCtD
Erlotinib—Asthenia—Timolol—glaucoma	7.14e-05	0.000407	CcSEcCtD
Erlotinib—Pruritus—Timolol—glaucoma	7.04e-05	0.000401	CcSEcCtD
Erlotinib—Diarrhoea—Timolol—glaucoma	6.8e-05	0.000388	CcSEcCtD
Erlotinib—Dizziness—Timolol—glaucoma	6.58e-05	0.000375	CcSEcCtD
Erlotinib—Vomiting—Timolol—glaucoma	6.32e-05	0.00036	CcSEcCtD
Erlotinib—Rash—Timolol—glaucoma	6.27e-05	0.000357	CcSEcCtD
Erlotinib—Dermatitis—Timolol—glaucoma	6.26e-05	0.000357	CcSEcCtD
Erlotinib—Headache—Timolol—glaucoma	6.23e-05	0.000355	CcSEcCtD
Erlotinib—Nausea—Timolol—glaucoma	5.91e-05	0.000337	CcSEcCtD
Erlotinib—MAP2K5—Signaling Pathways—NGFR—glaucoma	1.52e-05	0.000178	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—VEGFA—glaucoma	1.48e-05	0.000174	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CA1—glaucoma	1.47e-05	0.000173	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—GSTM1—glaucoma	1.47e-05	0.000173	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CA2—glaucoma	1.47e-05	0.000172	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CA1—glaucoma	1.47e-05	0.000172	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	1.46e-05	0.000171	CbGpPWpGaD
Erlotinib—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	1.45e-05	0.00017	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NTRK1—glaucoma	1.44e-05	0.000169	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—NOS3—glaucoma	1.44e-05	0.000169	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NGF—glaucoma	1.44e-05	0.000169	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.44e-05	0.000169	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.44e-05	0.000169	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CTSA—glaucoma	1.43e-05	0.000167	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CTSA—glaucoma	1.42e-05	0.000166	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—MMP9—glaucoma	1.41e-05	0.000165	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GSTT1—glaucoma	1.4e-05	0.000164	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—BAD—glaucoma	1.38e-05	0.000162	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—C3—glaucoma	1.37e-05	0.00016	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CA2—glaucoma	1.35e-05	0.000158	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CA2—glaucoma	1.34e-05	0.000157	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MMP2—glaucoma	1.34e-05	0.000157	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CDKN2B—glaucoma	1.33e-05	0.000156	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HDAC9—glaucoma	1.33e-05	0.000156	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—BAD—glaucoma	1.32e-05	0.000155	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.32e-05	0.000154	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.32e-05	0.000154	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.31e-05	0.000154	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.31e-05	0.000154	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GSTT1—glaucoma	1.3e-05	0.000153	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CA1—glaucoma	1.28e-05	0.000151	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SOD1—glaucoma	1.28e-05	0.00015	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CDKN1B—glaucoma	1.28e-05	0.00015	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EDN1—glaucoma	1.28e-05	0.00015	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—APOE—glaucoma	1.27e-05	0.000149	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—VEGFA—glaucoma	1.27e-05	0.000149	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NOS3—glaucoma	1.26e-05	0.000148	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CAV1—glaucoma	1.26e-05	0.000148	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CTSA—glaucoma	1.24e-05	0.000146	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	1.24e-05	0.000145	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL1A—glaucoma	1.23e-05	0.000145	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CA1—glaucoma	1.21e-05	0.000142	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FN1—glaucoma	1.2e-05	0.000141	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GSTT1—glaucoma	1.19e-05	0.000139	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—BAD—glaucoma	1.19e-05	0.000139	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MMP9—glaucoma	1.18e-05	0.000138	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CA2—glaucoma	1.17e-05	0.000138	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	1.17e-05	0.000138	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NGF—glaucoma	1.17e-05	0.000138	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CTSA—glaucoma	1.17e-05	0.000137	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—EDN1—glaucoma	1.16e-05	0.000136	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CDKN1B—glaucoma	1.12e-05	0.000132	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—C3—glaucoma	1.11e-05	0.000131	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ABCA1—glaucoma	1.11e-05	0.000131	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CYP1B1—glaucoma	1.11e-05	0.000131	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CA2—glaucoma	1.11e-05	0.00013	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TXN—glaucoma	1.1e-05	0.000129	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CDKN1B—glaucoma	1.1e-05	0.000128	CbGpPWpGaD
Erlotinib—ABL1—Immune System—C3—glaucoma	1.08e-05	0.000127	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—VEGFA—glaucoma	1.06e-05	0.000124	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL1A—glaucoma	1.05e-05	0.000123	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.05e-05	0.000123	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ABCA1—glaucoma	1.04e-05	0.000122	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SMO—glaucoma	1.04e-05	0.000122	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—APOE—glaucoma	1.04e-05	0.000122	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—VEGFA—glaucoma	1.04e-05	0.000122	CbGpPWpGaD
Erlotinib—ABL1—Immune System—BCL2L1—glaucoma	1.04e-05	0.000122	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TXN—glaucoma	1.04e-05	0.000121	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CAV1—glaucoma	1.03e-05	0.000121	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CA1—glaucoma	1.02e-05	0.00012	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN2B—glaucoma	1.02e-05	0.00012	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MMP9—glaucoma	1.01e-05	0.000119	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—C3—glaucoma	1.01e-05	0.000119	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MMP9—glaucoma	1.01e-05	0.000118	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CTSA—glaucoma	9.93e-06	0.000116	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—VEGFA—glaucoma	9.91e-06	0.000116	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FN1—glaucoma	9.79e-06	0.000115	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MMP1—glaucoma	9.78e-06	0.000115	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	9.76e-06	0.000114	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—BAD—glaucoma	9.67e-06	0.000113	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CDKN1B—glaucoma	9.6e-06	0.000113	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NOS3—glaucoma	9.54e-06	0.000112	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NTRK2—glaucoma	9.5e-06	0.000111	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TXN—glaucoma	9.5e-06	0.000111	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ABCA1—glaucoma	9.45e-06	0.000111	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CYP1B1—glaucoma	9.45e-06	0.000111	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—glaucoma	9.45e-06	0.000111	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TXN—glaucoma	9.44e-06	0.000111	CbGpPWpGaD
Erlotinib—ABL1—Immune System—BAD—glaucoma	9.39e-06	0.00011	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—CAV1—glaucoma	9.38e-06	0.00011	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CA2—glaucoma	9.37e-06	0.00011	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—glaucoma	9.36e-06	0.00011	CbGpPWpGaD
Erlotinib—EGFR—Immune System—C3—glaucoma	9.25e-06	0.000109	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CDKN1B—glaucoma	9.22e-06	0.000108	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	9.16e-06	0.000107	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	9.16e-06	0.000107	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—VEGFA—glaucoma	9.11e-06	0.000107	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TNF—glaucoma	9.06e-06	0.000106	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—VEGFA—glaucoma	9.04e-06	0.000106	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—FN1—glaucoma	8.92e-06	0.000105	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GSTM1—glaucoma	8.91e-06	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Immune System—BCL2L1—glaucoma	8.86e-06	0.000104	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—glaucoma	8.66e-06	0.000102	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—APOE—glaucoma	8.61e-06	0.000101	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—glaucoma	8.58e-06	0.000101	CbGpPWpGaD
Erlotinib—EGFR—Disease—MTHFR—glaucoma	8.54e-06	0.0001	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—CAV1—glaucoma	8.54e-06	0.0001	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTT1—glaucoma	8.5e-06	9.97e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	8.36e-06	9.81e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GSTM1—glaucoma	8.31e-06	9.74e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TXN—glaucoma	8.27e-06	9.7e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CDKN1B—glaucoma	8.26e-06	9.69e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NGFR—glaucoma	8.15e-06	9.56e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTT1—glaucoma	8.03e-06	9.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—BAD—glaucoma	8.03e-06	9.41e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—APOE—glaucoma	7.95e-06	9.33e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CA1—glaucoma	7.91e-06	9.28e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CAV1—glaucoma	7.88e-06	9.24e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—MTHFR—glaucoma	7.87e-06	9.23e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—glaucoma	7.84e-06	9.19e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TXN—glaucoma	7.8e-06	9.14e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NOS3—glaucoma	7.77e-06	9.12e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TNF—glaucoma	7.75e-06	9.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NTRK1—glaucoma	7.74e-06	9.08e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CTSA—glaucoma	7.66e-06	8.98e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MMP9—glaucoma	7.65e-06	8.97e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GSTM1—glaucoma	7.56e-06	8.86e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—BAD—glaucoma	7.41e-06	8.69e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	7.37e-06	8.65e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTT1—glaucoma	7.36e-06	8.63e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—MTHFR—glaucoma	7.34e-06	8.61e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—APOE—glaucoma	7.33e-06	8.59e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTT1—glaucoma	7.32e-06	8.59e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CAV1—glaucoma	7.26e-06	8.51e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CA2—glaucoma	7.23e-06	8.48e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN2B—glaucoma	7.14e-06	8.37e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NOS3—glaucoma	7.09e-06	8.31e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—glaucoma	6.88e-06	8.07e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—glaucoma	6.87e-06	8.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EDN1—glaucoma	6.85e-06	8.03e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—APOE—glaucoma	6.83e-06	8.01e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP1B1—glaucoma	6.77e-06	7.94e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ABCA1—glaucoma	6.77e-06	7.94e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CAV1—glaucoma	6.77e-06	7.94e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CDKN1B—glaucoma	6.73e-06	7.9e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MTHFR—glaucoma	6.68e-06	7.83e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TXN—glaucoma	6.6e-06	7.74e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CDKN1B—glaucoma	6.54e-06	7.67e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	6.48e-06	7.59e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTT1—glaucoma	6.41e-06	7.52e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ABCA1—glaucoma	6.4e-06	7.5e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP1B1—glaucoma	6.4e-06	7.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NGF—glaucoma	6.29e-06	7.38e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MMP9—glaucoma	6.24e-06	7.32e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—APOE—glaucoma	6.22e-06	7.29e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CAV1—glaucoma	6.16e-06	7.22e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTT1—glaucoma	6.04e-06	7.09e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—glaucoma	6.03e-06	7.07e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—C3—glaucoma	5.98e-06	7.02e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	5.97e-06	7e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—NOS3—glaucoma	5.96e-06	6.99e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	5.94e-06	6.96e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	5.9e-06	6.92e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ABCA1—glaucoma	5.87e-06	6.88e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP1B1—glaucoma	5.87e-06	6.88e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP1B1—glaucoma	5.83e-06	6.84e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ABCA1—glaucoma	5.83e-06	6.84e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—glaucoma	5.6e-06	6.57e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDKN1B—glaucoma	5.59e-06	6.56e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APOE—glaucoma	5.57e-06	6.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CAV1—glaucoma	5.52e-06	6.47e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—NOS3—glaucoma	5.49e-06	6.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—glaucoma	5.45e-06	6.39e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTM1—glaucoma	5.41e-06	6.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FN1—glaucoma	5.25e-06	6.16e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—glaucoma	5.19e-06	6.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BAD—glaucoma	5.19e-06	6.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN1B—glaucoma	5.16e-06	6.05e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTT1—glaucoma	5.12e-06	6.01e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—NOS3—glaucoma	5.12e-06	6e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTM1—glaucoma	5.12e-06	6e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP1B1—glaucoma	5.11e-06	5.99e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ABCA1—glaucoma	5.11e-06	5.99e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—glaucoma	5.11e-06	5.99e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TXN—glaucoma	5.1e-06	5.98e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—glaucoma	5.02e-06	5.89e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ABCA1—glaucoma	4.82e-06	5.65e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP1B1—glaucoma	4.82e-06	5.65e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTHFR—glaucoma	4.79e-06	5.61e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTM1—glaucoma	4.69e-06	5.5e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—glaucoma	4.68e-06	5.49e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTM1—glaucoma	4.66e-06	5.47e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—NOS3—glaucoma	4.66e-06	5.46e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTHFR—glaucoma	4.52e-06	5.3e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—APOE—glaucoma	4.45e-06	5.22e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CAV1—glaucoma	4.41e-06	5.18e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—glaucoma	4.26e-06	5e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—glaucoma	4.23e-06	4.96e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—APOE—glaucoma	4.21e-06	4.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOS3—glaucoma	4.17e-06	4.89e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CAV1—glaucoma	4.17e-06	4.89e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—glaucoma	4.14e-06	4.86e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	4.13e-06	4.84e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—glaucoma	4.12e-06	4.83e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTM1—glaucoma	4.09e-06	4.79e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP1B1—glaucoma	4.08e-06	4.78e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ABCA1—glaucoma	4.08e-06	4.78e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTT1—glaucoma	3.95e-06	4.63e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—glaucoma	3.86e-06	4.53e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOE—glaucoma	3.86e-06	4.53e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTM1—glaucoma	3.85e-06	4.52e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOE—glaucoma	3.84e-06	4.5e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CAV1—glaucoma	3.82e-06	4.48e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CAV1—glaucoma	3.8e-06	4.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1B—glaucoma	3.61e-06	4.24e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—glaucoma	3.61e-06	4.23e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—glaucoma	3.4e-06	3.99e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOE—glaucoma	3.36e-06	3.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—glaucoma	3.35e-06	3.93e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NOS3—glaucoma	3.34e-06	3.91e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CAV1—glaucoma	3.33e-06	3.91e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTM1—glaucoma	3.26e-06	3.83e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOE—glaucoma	3.17e-06	3.72e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NOS3—glaucoma	3.15e-06	3.7e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCA1—glaucoma	3.15e-06	3.69e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1B1—glaucoma	3.15e-06	3.69e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CAV1—glaucoma	3.14e-06	3.68e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—glaucoma	3.05e-06	3.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—glaucoma	3.01e-06	3.53e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NOS3—glaucoma	2.89e-06	3.39e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—glaucoma	2.88e-06	3.38e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—glaucoma	2.88e-06	3.38e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NOS3—glaucoma	2.87e-06	3.37e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOE—glaucoma	2.68e-06	3.15e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CAV1—glaucoma	2.66e-06	3.12e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—glaucoma	2.64e-06	3.1e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—glaucoma	2.63e-06	3.08e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NOS3—glaucoma	2.52e-06	2.95e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTM1—glaucoma	2.52e-06	2.95e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NOS3—glaucoma	2.37e-06	2.78e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—glaucoma	2.3e-06	2.7e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—glaucoma	2.27e-06	2.66e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—glaucoma	2.22e-06	2.61e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—glaucoma	2.17e-06	2.55e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOE—glaucoma	2.07e-06	2.43e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CAV1—glaucoma	2.05e-06	2.41e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NOS3—glaucoma	2.01e-06	2.36e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—glaucoma	1.84e-06	2.16e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NOS3—glaucoma	1.55e-06	1.82e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—glaucoma	1.42e-06	1.66e-05	CbGpPWpGaD
